PMGC Holdings Expands Assets 43% to $12.87M, Advances EL-22 Phase 2 Path
PMGC Holdings raised total assets by 43% to $12.87 million and shareholders’ equity to $7.84 million in fiscal 2025 through three acquisitions in precision manufacturing and IT packaging. Its biopharma subsidiary secured FDA feedback supporting a Phase 2 trial for EL-22 probiotic in combination with GLP-1 therapies.
1. Asset and Equity Expansion
PMGC expanded total assets from $8.99 million to $12.87 million and increased shareholders’ equity from $6.66 million to $7.84 million in fiscal 2025, reflecting disciplined capital deployment and balance sheet strengthening.
2. Strategic Manufacturing and Packaging Acquisitions
The company completed three acquisitions—Pacific Sun Packaging, AGA Precision Systems, and Indarg Engineering—bolstering its portfolio in mission-critical IT hardware packaging and ITAR-certified precision machining with established blue-chip customer bases.
3. Biopharma EL-22 Phase 2 Path
Northstrive Biosciences, PMGC’s biotech arm, received FDA feedback sufficient to support a Phase 2 IND submission for EL-22, an engineered probiotic targeting muscle preservation alongside GLP-1 weight loss treatments, while initiating preclinical studies for EL-32.